Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 185

1.

Treosulfan-based or busulfan-based conditioning for allogeneic transplantation: the role of dose intensity.

Shimoni A.

Lancet Haematol. 2019 Oct 9. pii: S2352-3026(19)30198-X. doi: 10.1016/S2352-3026(19)30198-X. [Epub ahead of print] No abstract available.

PMID:
31606446
2.

Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis.

Shouval R, Vega Y, Fein JA, Danylesko I, Shem Tov N, Yerushalmi R, Sobas M, Czyż A, Nagler A, Shimoni A.

Bone Marrow Transplant. 2019 Aug 28. doi: 10.1038/s41409-019-0653-7. [Epub ahead of print]

PMID:
31462682
3.

Risk factors and implications of oral mucositis in recipients of allogeneic hematopoietic stem cell transplantation.

Shouval R, Kouniavski E, Fein J, Danylesko I, Shem-Tov N, Geva M, Yerushalmi R, Shimoni A, Nagler A.

Eur J Haematol. 2019 Oct;103(4):402-409. doi: 10.1111/ejh.13299. Epub 2019 Aug 12.

PMID:
31332836
4.

The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators.

Beider K, Bitner H, Voevoda-Dimenshtein V, Rosenberg E, Sirovsky Y, Magen H, Canaani J, Ostrovsky O, Shilo N, Shimoni A, Abraham M, Weiss L, Milyavsky M, Peled A, Nagler A.

Biochem Pharmacol. 2019 Oct;168:412-428. doi: 10.1016/j.bcp.2019.07.016. Epub 2019 Jul 17.

PMID:
31325448
5.

Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Shimoni A, Labopin M, Savani B, Byrne M, Volin L, Finke J, Niederwieser D, Ehninger G, Blaise D, Beelen D, Tabrizi R, Sengeloev H, Ganser A, Cornelissen JJ, Mohty M, Nagler A.

Biol Blood Marrow Transplant. 2019 Nov;25(11):2251-2260. doi: 10.1016/j.bbmt.2019.06.031. Epub 2019 Jul 2.

PMID:
31271887
6.

A simplified method for detection of N-terminal valine adducts in patients receiving treosulfan.

Boysen G, Shimoni A, Danylesko I, Varda-Bloom N, Nagler A.

Rapid Commun Mass Spectrom. 2019 Nov 15;33(21):1635-1642. doi: 10.1002/rcm.8509.

PMID:
31240802
7.

External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation.

Shouval R, Fein JA, Shouval A, Danylesko I, Shem-Tov N, Zlotnik M, Yerushalmi R, Shimoni A, Nagler A.

Blood Adv. 2019 Jun 25;3(12):1881-1890. doi: 10.1182/bloodadvances.2019032268.

8.

Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation.

Nagler A, Labopin M, Dholaria B, Finke J, Brecht A, Schanz U, Niittyvuopio R, Neubauer A, Bornhäuser M, Santarone S, Beelen D, Shimoni A, Rösler W, Giebel S, Savani BN, Mohty M.

Br J Haematol. 2019 Sep;186(5):767-776. doi: 10.1111/bjh.15973. Epub 2019 May 22.

PMID:
31115916
9.

Early and late hematologic toxicity following CD19 CAR-T cells.

Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, Shimoni A, Nagler A, Toren A, Jacoby E.

Bone Marrow Transplant. 2019 Oct;54(10):1643-1650. doi: 10.1038/s41409-019-0487-3. Epub 2019 Feb 26.

PMID:
30809033
10.

Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease.

Danylesko I, Bukauskas A, Paulson M, Peceliunas V, Gedde-Dahl D Y T, Shimoni A, Shouval R, Griskevicius L, Floisand Y, Nagler A.

Bone Marrow Transplant. 2019 Jul;54(7):987-993. doi: 10.1038/s41409-018-0364-5. Epub 2018 Oct 24.

PMID:
30356163
11.

Identification of strong intron enhancer in the heparanase gene: effect of functional rs4693608 variant on HPSE enhancer activity in hematological and solid malignancies.

Ostrovsky O, Grushchenko-Polaq AH, Beider K, Mayorov M, Canaani J, Shimoni A, Vlodavsky I, Nagler A.

Oncogenesis. 2018 Jun 29;7(6):51. doi: 10.1038/s41389-018-0060-8.

12.

The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation.

Fein JA, Shimoni A, Labopin M, Shem-Tov N, Yerushalmi R, Magen H, Furie N, Kopel E, Danylesko I, Nagler A, Shouval R.

Leukemia. 2018 Aug;32(8):1787-1794. doi: 10.1038/s41375-018-0185-y. Epub 2018 Jun 27.

PMID:
29950692
13.

Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide.

Shimoni A, Labopin M, Lorentino F, Van Lint MT, Koc Y, Gülbas Z, Tischer J, Bruno B, Blaise D, Pioltelli P, Afanasyev B, Ciceri F, Mohty M, Nagler A.

Leukemia. 2019 Jan;33(1):230-239. doi: 10.1038/s41375-018-0170-5. Epub 2018 Jun 15.

PMID:
29907809
14.

CAR T cells induce a complete response in refractory Burkitt Lymphoma.

Avigdor A, Shouval R, Jacoby E, Davidson T, Shimoni A, Besser M, Nagler A.

Bone Marrow Transplant. 2018 Dec;53(12):1583-1585. doi: 10.1038/s41409-018-0235-0. Epub 2018 May 24. No abstract available.

PMID:
29795432
15.

Baseline Renal Function and Albumin are Powerful Predictors for Allogeneic Transplantation-Related Mortality.

Shouval R, de Jong CN, Fein J, Broers AEC, Danylesko I, Shimoni A, Reurs MR, Baars AE, van der Schaft N, Nagler A, Cornelissen JJ.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1685-1691. doi: 10.1016/j.bbmt.2018.05.005. Epub 2018 May 9.

16.

Second Malignancies after Hematopoietic Stem Cell Transplantation.

Danylesko I, Shimoni A.

Curr Treat Options Oncol. 2018 Feb 8;19(2):9. doi: 10.1007/s11864-018-0528-y. Review.

PMID:
29423555
17.

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission.

Saraceni F, Labopin M, Hamladji RM, Mufti G, Socié G, Shimoni A, Delage J, Deconinck E, Chevallier P, Blaise D, Sanz J, Huynh A, Forcade E, Savani BN, Mohty M, Nagler A; Acute Leukemia Working Party of the European society for Blood and Marrow Transplantation (EBMT).

Oncotarget. 2017 Dec 15;9(3):3379-3393. doi: 10.18632/oncotarget.23273. eCollection 2018 Jan 9.

18.

The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis.

Lorentino F, Labopin M, Fleischhauer K, Ciceri F, Mueller CR, Ruggeri A, Shimoni A, Bornhäuser M, Bacigalupo A, Gülbas Z, Koc Y, Arcese W, Bruno B, Tischer J, Blaise D, Messina G, Beelen DW, Nagler A, Mohty M.

Blood Adv. 2017 Apr 21;1(11):669-680. doi: 10.1182/bloodadvances.2017006429. eCollection 2017 Apr 25.

19.

Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation.

Shimoni A, Labopin M, Savani B, Hamladji RM, Beelen D, Mufti G, Socié G, Delage J, Blaise D, Chevallier P, Forcade E, Deconinck E, Mohty M, Nagler A.

Biol Blood Marrow Transplant. 2018 Apr;24(4):751-757. doi: 10.1016/j.bbmt.2017.12.776. Epub 2017 Dec 13.

20.

Dissecting the mechanisms involved in anti-human T-lymphocyte immunoglobulin (ATG)-induced tolerance in the setting of allogeneic stem cell transplantation - potential implications for graft versus host disease.

Beider K, Naor D, Voevoda V, Ostrovsky O, Bitner H, Rosenberg E, Varda-Bloom N, Marcu-Malina V, Canaani J, Danilesko I, Shimoni A, Nagler A.

Oncotarget. 2017 Oct 11;8(53):90748-90765. doi: 10.18632/oncotarget.21797. eCollection 2017 Oct 31.

21.

Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.

Shimoni A, Vago L, Bernardi M, Yerushalmi R, Peccatori J, Greco R, Shem-Tov N, Lo Russo A, Danylesko I, Apel A, Bonini C, Lupo Stanghellini MT, Nagler A, Ciceri F.

Am J Hematol. 2017 Oct;92(10):1011-1019. doi: 10.1002/ajh.24827. Epub 2017 Jul 19.

22.

Isolated Extramedullary Relapse of Acute Leukemia after Allogeneic Stem Cell Transplantation: Different Kinetics and Better Prognosis than Systemic Relapse.

Shem-Tov N, Saraceni F, Danylesko I, Shouval R, Yerushalmi R, Nagler A, Shimoni A.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1087-1094. doi: 10.1016/j.bbmt.2017.03.023. Epub 2017 Apr 7.

23.

Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Nagler A, Labopin M, Beelen D, Ciceri F, Volin L, Shimoni A, Foá R, Milpied N, Peccatori J, Polge E, Mailhol A, Mohty M, Savani BN.

Cancer. 2017 Jul 15;123(14):2671-2679. doi: 10.1002/cncr.30646. Epub 2017 Mar 22.

24.

The role of stem-cell transplantation in the treatment of marginal zone lymphoma.

Shimoni A.

Best Pract Res Clin Haematol. 2017 Mar - Jun;30(1-2):166-171. doi: 10.1016/j.beha.2016.08.027. Epub 2016 Nov 5. Review.

PMID:
28288712
25.

The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors.

Yerushalmi R, Shem-Tov N, Danylesko I, Shouval R, Nagler A, Shimoni A.

Am J Hematol. 2017 Mar;92(3):259-268. doi: 10.1002/ajh.24631. Epub 2017 Feb 1.

26.

Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia.

Varda-Bloom N, Danylesko I, Shouval R, Eldror S, Lev A, Davidson J, Rosenthal E, Volchek Y, Shem-Tov N, Yerushalmi R, Shimoni A, Somech R, Nagler A.

Oncotarget. 2017 Jan 3;8(1):418-429. doi: 10.18632/oncotarget.13439.

27.

Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation.

Shimoni A, Labopin M, Savani B, Volin L, Ehninger G, Kuball J, Bunjes D, Schaap N, Vigouroux S, Bacigalupo A, Veelken H, Sierra J, Eder M, Niederwieser D, Mohty M, Nagler A.

J Hematol Oncol. 2016 Nov 8;9(1):118.

28.

The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway.

Beider K, Rosenberg E, Bitner H, Shimoni A, Leiba M, Koren-Michowitz M, Ribakovsky E, Klein S, Olam D, Weiss L, Wald H, Abraham M, Galun E, Peled A, Nagler A.

Clin Cancer Res. 2017 Apr 1;23(7):1733-1747. doi: 10.1158/1078-0432.CCR-15-2618. Epub 2016 Oct 3.

29.

Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas.

van Gorkom G, Finel H, Giebel S, Pohlreich D, Shimoni A, Ringhoffer M, Sucak G, Schaap N, Dreger P, Sureda A, Schouten HC.

J Clin Apher. 2017 Oct;32(5):295-301. doi: 10.1002/jca.21506. Epub 2016 Sep 10.

PMID:
27614935
30.

Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation.

Tsirigotis P, Danylesko I, Gkirkas K, Shem-Tov N, Yerushalmi R, Stamouli M, Avigdor A, Spyridonidis A, Gauthier J, Goldstein G, Apostolidis J, Mohty M, Shimoni A, Nagler A.

Bone Marrow Transplant. 2016 Oct;51(10):1313-1317. doi: 10.1038/bmt.2016.129. Epub 2016 May 16.

PMID:
27183095
31.

Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study.

Shouval R, Labopin M, Unger R, Giebel S, Ciceri F, Schmid C, Esteve J, Baron F, Gorin NC, Savani B, Shimoni A, Mohty M, Nagler A.

PLoS One. 2016 Mar 4;11(3):e0150637. doi: 10.1371/journal.pone.0150637. eCollection 2016.

32.

Radioimmunotherapy and Autologous Stem-Cell Transplantation in the Treatment of B-Cell Non-Hodgkin Lymphoma.

Shimoni A, Zwas ST.

Semin Nucl Med. 2016 Mar;46(2):119-25. doi: 10.1053/j.semnuclmed.2015.10.009. Review.

PMID:
26897716
33.

Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.

Danylesko I, Sareli R, Bloom-Varda N, Yerushalmi R, Shem-Tov N, Shimoni A, Nagler A.

Biol Blood Marrow Transplant. 2016 Feb;22(2):277-283. doi: 10.1016/j.bbmt.2015.08.033. Epub 2015 Sep 4.

34.

Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot Study.

Danylesko I, Sareli R, Varda-Bloom N, Yerushalmi R, Shem-Tov N, Shimoni A, Nagler A.

Acta Haematol. 2016;135(1):29-36. doi: 10.1159/000435769. Epub 2015 Aug 22.

PMID:
26303343
35.

Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study.

Shouval R, Labopin M, Bondi O, Mishan-Shamay H, Shimoni A, Ciceri F, Esteve J, Giebel S, Gorin NC, Schmid C, Polge E, Aljurf M, Kroger N, Craddock C, Bacigalupo A, Cornelissen JJ, Baron F, Unger R, Nagler A, Mohty M.

J Clin Oncol. 2015 Oct 1;33(28):3144-51. doi: 10.1200/JCO.2014.59.1339. Epub 2015 Aug 3.

36.

Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies.

Yerushalmi R, Shem-Tov N, Danylesko I, Avigdor A, Nagler A, Shimoni A.

Bone Marrow Transplant. 2015 Dec;50(12):1526-35. doi: 10.1038/bmt.2015.174. Epub 2015 Aug 3.

PMID:
26237166
37.

Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients.

Koren-Michowitz M, Shimoni A, Daraio F, Crasto F, Lorenzatti R, Volchek Y, Amariglio N, Gottardi E, Saglio G, Nagler A.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1852-5. doi: 10.1016/j.bbmt.2015.06.018. Epub 2015 Jul 4.

38.

The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Rubio MT, Labopin M, Blaise D, Socié G, Contreras RR, Chevallier P, Sanz MA, Vigouroux S, Huynh A, Shimoni A, Bulabois CE, Caminos N, López-Corral L, Nagler A, Mohty M.

Haematologica. 2015 May;100(5):683-9. doi: 10.3324/haematol.2014.119339. Epub 2015 Mar 13.

39.

G-CSF-primed BM for allogeneic SCT: revisited.

Pessach I, Resnick I, Shimoni A, Nagler A.

Bone Marrow Transplant. 2015 Jul;50(7):892-8. doi: 10.1038/bmt.2015.25. Epub 2015 Mar 2. Review.

PMID:
25730185
40.

Cytomegalovirus retinitis in HIV-negative patients: a practical management approach.

Vishnevskia-Dai V, Shapira Y, Rahav G, Shimoni A, Somech R, Moisseiev J.

Ophthalmology. 2015 Apr;122(4):866-868.e3. doi: 10.1016/j.ophtha.2014.11.010. Epub 2014 Dec 31. No abstract available.

PMID:
25556113
41.

Chemotherapy dose adjustment for obese patients undergoing hematopoietic stem cell transplantation: a survey on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Shem-Tov N, Labopin M, Moukhtari L, Ciceri F, Esteve J, Giebel S, Gorin NC, Schmid C, Shimoni A, Nagler A, Mohty M.

Oncologist. 2015 Jan;20(1):50-5. doi: 10.1634/theoncologist.2014-0187. Epub 2014 Dec 5.

42.

Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.

Shimoni A, Volchek Y, Koren-Michowitz M, Varda-Bloom N, Somech R, Shem-Tov N, Yerushalmi R, Nagler A.

Cancer. 2015 Mar 15;121(6):863-71. doi: 10.1002/cncr.29141. Epub 2014 Nov 11.

43.

Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation.

Koren-Michowitz M, Maayan H, Apel A, Shem-Tov N, Yerushalmi R, Volchek Y, Avigdor A, Shimoni A, Nagler A.

Ann Hematol. 2015 Mar;94(3):375-8. doi: 10.1007/s00277-014-2229-3. Epub 2014 Oct 14.

PMID:
25307457
44.

Second malignancies after allogeneic stem cell transplantation with reduced-intensity conditioning: is the incidence reduced?

Shimoni A.

Biol Blood Marrow Transplant. 2014 Nov;20(11):1669-70. doi: 10.1016/j.bbmt.2014.09.004. Epub 2014 Sep 16. No abstract available.

45.

Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.

Mei M, Wondergem MJ, Palmer JM, Shimoni A, Hasenkamp J, Tsai NC, Simpson J, Nademanee A, Raubitschek A, Forman SJ, Krishnan AY.

Biol Blood Marrow Transplant. 2014 Dec;20(12):2072-5. doi: 10.1016/j.bbmt.2014.07.028. Epub 2014 Jul 29.

46.

Inkjet printing of flexible high-performance carbon nanotube transparent conductive films by "coffee ring effect".

Shimoni A, Azoubel S, Magdassi S.

Nanoscale. 2014 Oct 7;6(19):11084-9. doi: 10.1039/c4nr02133a.

PMID:
25014193
47.

The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.

Tsirigotis P, Shimoni A, Nagler A.

Ann Med. 2014 Sep;46(6):384-96. doi: 10.3109/07853890.2014.918463. Epub 2014 Jun 3. Review.

PMID:
24888385
48.

Outcome differences in patients with precursor B cell acute lymphocytic leukemia over time: a retrospective analysis.

Apel A, Kedmi M, Levi E, Berkowicz M, Davidovitz Y, Kneller A, Ribakovsky E, Shimoni A, Nagler A, Avigdor A.

Isr Med Assoc J. 2014 Apr;16(4):224-8.

49.

Risk stratification of patients with multiple myeloma prior to autologous stem cell transplant: what is the role of serum ferritin levels?

Shimoni A.

Leuk Lymphoma. 2014 Nov;55(11):2419-20. doi: 10.3109/10428194.2014.921915. Epub 2014 Jun 16. No abstract available.

PMID:
24828866
50.

Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Nagler A, Labopin M, Gorin NC, Ferrara F, Sanz MA, Wu D, Gomez AT, Lapusan S, Irrera G, Guimaraes JE, Sousa AB, Carella AM, Vey N, Arcese W, Shimoni A, Berger R, Rocha V, Mohty M.

Haematologica. 2014 Aug;99(8):1380-6. doi: 10.3324/haematol.2014.105197. Epub 2014 May 9.

Supplemental Content

Loading ...
Support Center